Atai Beckley Inc.

Atai Beckley Inc. is the company identified by ticker ATAI on this research page. Use the overview to review the business, financial results, valuation and related news.

Atai Beckley Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the discovery, advancement, and commercialization of innovative therapeutic solutions for a variety of mental health conditions. The company's operations extend across the United States, Germany, and Canada. Its development pipeline features several key compounds: BPL-003: An intranasally administered formulation of mebufotenin benzoate salt, currently undergoing Phase 2a and 2b clinical trials for its potential in treating both treatment-resistant depression (TRD) and alcohol use disorder. RL-007: An orally active, pro-cognitive neuromodulator, progressing through a Phase 2b study focused on cognitive impairment associated with schizophrenia. ELE-101: A serotonergic psychedelic compound designed to address major depressive disorder. VLS-01: An oral transmucosal film featuring N,N-Dimethyltryptamine, which is in a Phase 2 clinical study for TRD. EMP-01: An orally administered form of R-3,4-methylenedioxy-methamphetamine, also in Phase 2 trials for social anxiety disorder. EGX-A & EGX-B: Non-hallucinogenic 5-HT2A receptor agonists, which are being explored for treatment-resistant depression. Beyond these pipeline assets, the firm also provides COMP360 for psilocybin therapy and GRX-917, aimed at treating anxiety, depression, and various neurological conditions. Originally known as Atai Beckley N.V., the entity officially changed its name to Atai Beckley Inc. in December 2025. Established in 2018, its corporate headquarters are situated in New York, New York.

Check the ATAI quote and chart on the overview and Chart tabs. Confirm the quote time, currency and trading session before comparing prices; a research update time is not a quote timestamp.

The Forecast tab shows available analyst price targets for ATAI. Analyst targets are separate from BTI scores and valuation estimates. Missing targets are unavailable, and forecasts do not guarantee returns.

Review Atai Beckley Inc.'s investor-relations announcements for declared dividends, ex-dividend dates and payment dates. A missing or zero yield in a data feed alone does not establish the company's dividend policy.

Check the Earnings tab for available dates and reported results, then confirm the next announcement with Atai Beckley Inc.'s investor-relations calendar. Estimated dates may change.

Compare ATAI's Valuation and Financials tabs, including cash flow, growth assumptions and valuation multiples. BTI estimates depend on their inputs and are different from analyst price targets.

Review Atai Beckley Inc.'s latest company filings for business-specific risks, alongside debt, profitability, competition and valuation. A BTI score summarizes research and is not a personalized investment recommendation.